In this blog I want to tell the story of the pharmaceutical world. I will not just through my post, but also pointing out the major news affecting the industry and especially with the help of the many posts that I send
Ipsen (Paris:IPN) and its partner Medicis (NYSE: MRX) announced today that the companies are in active labeling and Risk Evaluation and Mitigation Strategy ("REMS") discussions with the U.S. Food and Drug Administration (“FDA”) related to the Biologics License Application (“BLA”) for Ipsen’s botulinum toxin type A product in both therapeutic and aesthetic indications.
